Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.44 |
| ▸ | GRK2 | P25098 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 4/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.40 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7677948 | 1.00 | PRCP (0.44) | PRCPGRK2MEN1KMT2AAKT1 | |
| SCHEMBL6688183 | 1.00 | PRCP (0.44) | PRCPGRK2MEN1KMT2AAKT1 | |
| Hydrochloric Acid SCHEMBL14658531 | 0.86 | MAPT (0.51) | PRCPGRK2MEN1KMT2AAKT1 | |
| Hydrochloric Acid SCHEMBL14658532 | 0.86 | MAPT (0.51) | PRCPGRK2MEN1KMT2AAKT1 | |
| SCHEMBL18252855 | 0.86 | GRK2 (0.43) | PRCPGRK2MEN1KMT2AAKT1 | |
| SCHEMBL13594749 | 0.85 | MAPT (0.52) | — | |
| SCHEMBL4000731 | 0.85 | MAPT (0.52) | — | |
| SCHEMBL1819020 | 0.85 | TACR1 (0.45) | SLC9A1 | |
| SCHEMBL1819018 | 0.85 | TACR1 (0.45) | SLC9A1 | |
| SCHEMBL16579327 | 0.85 | MAPT (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3174864-A2 | VMAT INHIBITORY COMPOUNDS | Oregon Health & Science University (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9546151-B2 | VMAT inhibitory compounds | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2017-01-17 | — | — | US | disclosed |
| WO-2016019312-A2 | VMAT INHIBITORY COMPOUNDS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2016-02-04 | — | — | WO | disclosed |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | WILMINGTON TRUST (LONDON) LIMITED, AS SECURITY AGENT (GB) | 2016-02-04 | — | — | US | disclosed |
| US-20020010155-A1 | Novel process | SMITHKLINE BEECHAM P.L.C. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170298042-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | PRCP 1321/4885GRK2 262/4885MEN1 3426/4885 |
| US-20160031852-A1 | VMAT INHIBITORY COMPOUNDS | SLC18A2, SLC18A3, SLC6A2 | PRCP 1321/4885GRK2 262/4885MEN1 3426/4885 |
| US-20020010155-A1 | Novel process | ADH1C, CBR1, ADH1A | PRCP 2819/4885GRK2 2867/4885MEN1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.